Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Study Results Show Promise for Osteoporosis Treatment

By Drug Discovery Trends Editor | March 23, 2016

An international study by The University of Western Australia may lead to a new treatment for osteoporosis caused by age-related bone loss in elderly women.

Osteoporosis is a common disease which makes bones become brittle and leads to a higher risk of breaks than in normal bone. It affects more than one million Australians and is known as the silent disease, because you rarely know you have it until you actually break a bone.

It occurs when bones lose minerals, such as calcium, more quickly than the body can replace them, causing a loss of bone thickness.

The new research, published in Nature Communications, found a new way that cells involved in bone structure were able to talk to each other.

Professor Jiake Xu from UWA’s School of Pathology and Laboratory Medicine said researchers focused on two types of cells, bone-resorbing osteoclasts which break down bone and bone-forming osteoblasts that regularly cross-talk within the body.

“Bone remodelling is regulated by these two types of cells that communicate with each other in several ways,” he said.

“One classic way that they do this is by making a protein, then secreting it and binding it to the receptor of another cell, or through cell-to-cell contact.”

Professor Xu said the new research found that osteoclasts could also produce, small  sac-like structures containing  MicroRNAs, or information, that could communicate with other cells.

“We’ve discovered the osteoclasts can send a message to osteoblasts about inhibiting bone growth, so if we could find a way to manipulate this to instead promote bone growth it could lead to new treatments for osteoporosis,” he said.

The research is the latest collaboration between Professor Xu and Professor Ge Zhang and Aiping Lu,from the Hong Kong Baptist University (HKBU).

Source: University of Western Australia 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50